Skip to content
Shorla Oncology: A Leader in Innovative Oncology Solutions
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • TEPYLUTE
    • IMKELDI
    • JYLAMVO
    • Nelarabine Injection
  • Pipeline
  • News
    • Company Updates
    • Media
  • Careers
  • Contact

Company Updates

Shorla Oncology Proud to Attend the NCODA International fall summit

November 12th 2025November 12th 2025

Read More

Shorla Oncology Proud to be a Sponsor at the OneOncology Annual Conference

November 13th 2025November 12th 2025

Read More

Shorla Oncology Proud to Participate at FCS 2025 Clinical Summit

November 12th 2025October 10th 2025

Read More

Shorla Oncology Exhibits AT THE 49th Annual APHON Conference

November 12th 2025September 25th 2025

Read More

Shorla Oncology Attends Children Oncology Group Meeting

November 12th 2025September 16th 2025

Read More

Shorla Oncology Proud to Attend the NCODA Oncology Institute Meeting

November 12th 2025August 13th 2025

Read More

BW

SH-110 Receives FDA Orphan Drug Designation for Rare Brain Cancer

July 17th 2025July 16th 2025

Read More

Shorla Oncology Attends ATOPP Summit 2025

November 12th 2025July 9th 2025

Read More

Shorla Oncology Attends 2025 Cardinal Health™ NOC

November 12th 2025June 29th 2025

Read More

Older posts
Page1 Page2 … Page13
Logo

IRELAND HQ:
Questum Acceleration Center,
Ballingarrane Science & Technology Park,
Clonmel, Co. Tipperary,
E91 V329, Ireland

Shorla Pharma Ltd trading as Shorla Oncology®

All trademarks are the property of their respective owners.

US OFFICE:
245 Main St.,
2nd floor,
Cambridge,
MA 02142, USA

SITEMAP

PRIVACY POLICY

CALIFORNIA COMPLIANCE PROGRAM DECLARATION

Company number: 618033
©SHORLA ONCOLOGY® 2025

© 2025 Shorla Oncology: A Leader in Innovative Oncology Solutions • Built with GeneratePress
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • TEPYLUTE
    • IMKELDI
    • JYLAMVO
    • Nelarabine Injection
  • Pipeline
  • News
    • Company Updates
    • Media
  • Careers
  • Contact

Now approved for use in Pediatrics

  • Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA).
  • Treatment of pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen.

Please click here for the full Prescribing information, including Boxed Warning regarding embryo-fetal toxicity, hypersensitivity reactions, and severe adverse reactions.